Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec …
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
Dec 30, 2024 · The stock had quadrupled this year before Sangamo disclosed Pfizer’s decision. ... The company’s market value was just below $500 million before the Pfizer news hit.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
6 days ago · On Monday, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational …
Sangamo shares plunge after Pfizer ends hemophilia A gene …
Dec 30, 2024 · Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% …
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia …
Dec 31, 2024 · Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped …
Sangamo Therapeutics to Regain Full Rights to ... - Business Wire
Dec 30, 2024 · These risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo’s Annual …
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene …
6 days ago · Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. …
Pfizer Ends Sangamo Partnership for Hemophilia Therapy
Dec 30, 2024 · Sangamo and Pfizer together developed the treatment, called giroctocogene fitelparvovec, and it was licensed to Pfizer. ... Dow Jones Newswires is a market-moving …
Sangamo Therapeutics Stock Crashes as Pfizer Ends
6 days ago · Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement. The two drugmakers were working on a treatment for hemophilia …
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
Dec 30, 2024 · Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A.